These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10533322)

  • 41. Efficacy of gonadotropin-releasing hormone agonist (buserelin) in the treatment of endometriosis.
    Rönnberg L; Koskimies A; Laatikainen T; Ranta T; Saastamoinen J
    Acta Obstet Gynecol Scand; 1989; 68(1):49-53. PubMed ID: 2508418
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GnRH-agonist therapy in women with the polycystic ovarian syndrome: effects on ovarian volume and on gonadotropin and sex steroid levels.
    Dale PO; Tanbo T; Haug E; Abyholm T
    Gynecol Endocrinol; 1989 Dec; 3(4):309-15. PubMed ID: 2516706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Contraception by cyclic treatment with buserelin and progesterone].
    Wieacker P; Breckwoldt M; Greif M; Geisthövel F
    Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):135-9. PubMed ID: 1904039
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
    Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of endometriosis with gonadotropin releasing hormone agonist (buserelin).
    Sirimongkolkasem R; Rojanasakul A; Chailurkit LO
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():37-41. PubMed ID: 2112582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial.
    Gong L; Zhang S; Han Y; Long Q; Zou S; Cao Y
    J Clin Pharmacol; 2015 Aug; 55(8):848-53. PubMed ID: 25694383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A preliminary report on the comparative use of buserelin (Hoe 766) and danazol in the treatment of endometriosis: the University of Southern California experience.
    Yee B
    Prog Clin Biol Res; 1986; 225():175-88. PubMed ID: 3097664
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin).
    Schriock E; Monroe SE; Henzl M; Jaffe RB
    Fertil Steril; 1985 Nov; 44(5):583-8. PubMed ID: 2932349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial.
    Franke HR; van de Weijer PH; Pennings TM; van der Mooren MJ
    Fertil Steril; 2000 Sep; 74(3):534-9. PubMed ID: 10973651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol.
    Dawood MY; Lewis V; Ramos J
    Fertil Steril; 1989 Jul; 52(1):21-6. PubMed ID: 2501109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gonadotrophin releasing hormone agonist suppressive treatment of ovarian function decreases serum LH-beta and bioactive LH but maintains elevated levels of LH-alpha.
    Lemay A; Lourdusamy M
    Clin Endocrinol (Oxf); 1991 Mar; 34(3):191-6. PubMed ID: 1709841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
    Cedars MI; Lu JK; Meldrum DR; Judd HL
    Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol.
    Dodin S; Lemay A; Maheux R; Dumont M; Turcot-Lemay L
    Obstet Gynecol; 1991 Mar; 77(3):410-5. PubMed ID: 1825135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
    Surrey ES; Voigt B; Fournet N; Judd HL
    Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Studies on endocrine therapy of endometriosis].
    Terakawa N
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Aug; 41(8):981-9; discussion 1000-7. PubMed ID: 2530291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
    Marshall LA; Cain DF; Dmowski WP; Chesnut CH
    Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis.
    Meldrum DR; Chang RJ; Lu J; Vale W; Rivier J; Judd HL
    J Clin Endocrinol Metab; 1982 May; 54(5):1081-3. PubMed ID: 6801075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment with nafarelin for endometriosis in young women. Efficacy, safety and lipid metabolism. Niigata Nafarelin Study Group.
    Kurabayashi T; Takakuwa K; Tanaka K
    J Reprod Med; 2000 Jun; 45(6):454-60. PubMed ID: 10900577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Add-back therapy in the treatment of endometriosis: the European experience.
    Edmonds DK
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.